Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
TGTX Stock Chart & Stats
$34.04
$0.31(1.11%)
At close: 4:00 PM EST
$34.04
$0.31(1.11%)
Day’s Range― - ―
52-Week Range$25.28 - $46.48
Previous CloseN/A
Volume723.16K
Average Volume (3M)1.77M
Market Cap
$5.36B
Enterprise ValueN/A
Total Cash (Recent Filing)$251.87M
Total Debt (Recent Filing)$253.72M
Price to Earnings (P/E)12.2
Beta1.28
Next Earnings
Mar 03, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.43
Shares Outstanding158,665,620
10 Day Avg. Volume2,223,843
30 Day Avg. Volume1,773,348
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)19.67
Price to Sales (P/S)13.29
P/FCF Ratio-107.84
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$45.00Price Target Upside32.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.75
Revenue Forecast (FY)$588.09M
Bulls Say, Bears Say
Bulls Say
Market ExpansionBriumvi is now commercially available in additional countries in the EU, UK, Switzerland, and Australia, which could translate into incrementally larger royalty revenue in the quarters ahead.
Product DemandGrowth in Q3 was driven by a combination of record enrollments and repeat prescriptions, both of which exceeded the company's internal expectations.
Revenue GrowthBriumvi revenues slightly above consensus; full-year US revenue guidance increased to $585M, indicating the company's strong financial performance.
Bears Say
Revenue ExpectationsThe raised guidance of $570-575M for 2025 Briumvi revenue seems to be baked into shares in our view given consensus full-year expectations were at $578M before the print.
Share Price PerformanceTGTX shares are trading down -14% after announcing a 2Q print of $138.8M for Briumvi which was above company guidance but in line with analyst expectations.
Subcutaneous Market CompetitionTG’s subq option is behind relative to approved subq options and may ultimately face an uphill battle in what we view as a growing section of the MS population.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $25.28 and its highest was $46.48 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $5.36B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Mar 03, 2026 which is in 117 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Nov 03, 2025. The company reported $2.43 earnings per share for the quarter, beating the consensus estimate of $0.219 by $2.211.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.33.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 158,665,620 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $2.43 in its last earnings report, beating expectations of $0.219. Following the earnings report the stock price went down -3.134%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
TG Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (32.20% Upside)
$45.00 (32.20% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 80%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 160.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $672.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
31.63%
12-Months-Change
Fundamentals
Return on Equity
111.96%
Trailing 12-Months
Asset Growth
74.91%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TGTX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, positive developments in clinical trials, and an increase in market presence and revenue guidance. However, there were challenges with increased operating expenses and limited ex-U.S. sales growth. Overall, the highlights significantly outweigh the lowlights.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$45.00
▲(32.20% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Ownership Overview
9.80% Insiders
18.76% Mutual Funds
0.07% Other Institutional Investors
48.62% Public Companies and
Individual Investors